Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

BACKGROUND: Nintedanib (Ofev(®)) and pirfenidone (Esbriet(®)) are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF). OBJECTIVES: To compare the cost-effectiveness of nintedanib with that of pirfenidone for the treatment of IPF from a Belgian healthc...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Pharmacoecon Open
Main Authors: Rinciog, C., Diamantopoulos, A., Gentilini, A., Bondue, B., Dahlqvist, C., Froidure, A., Wuyts, W. A., Soulard, S.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2020
Teme:
Original Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7426351/
https://ncbi.nlm.nih.gov/pubmed/31939146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-00191-w
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki